Start an analysis for WST
West Pharmaceutical Services, Inc.
Stock · NYSEProgram summary
| Field | Value | As of | Source |
|---|---|---|---|
| Current authorization | $1.0bn | 30-Sep-26 | 10-Q filed 29-Oct-26 |
| Remaining authorization | $315m | 30-Sep-26 | 10-Q filed 29-Oct-26 |
| Program expiry | n/a | — | |
| Repurchased last quarter | $231m | 30-Sep-26 | 10-Q filed 29-Oct-26 |
| Has used an ASR | No | — |
Programs
| Authorized on | Authorized | Remaining | Expires | Terms |
|---|---|---|---|---|
| Not found in filings | $1.0bn | $315mEST | n/a | In February 2026, the Company’s Board of Directors authorized a new share repurchase program for the purchase of up to $1.0 billion of the Company’s common stock in open-market transactions, block transactions, through derivative transactions, privately negotiated transactions, or otherwise, including pursuant to any trading plan entered into by the Company under Rule 10b5-1 of the Exchange Act.10-Q filed 29-Oct-26 |
Open-market repurchases
- Apr ’26
- May ’26
- Jun ’26
- Jul ’26
- Aug ’26
- Sep ’26
| Month ended | Shares | Avg price | ≈ Value | Source |
|---|---|---|---|---|
| 30-Sep-26 | 154,301 | $355.79 | $55m | 10-Q filed 29-Oct-26 |
| 31-Aug-26 | 323,689 | $349.61 | $113m | 10-Q filed 29-Oct-26 |
| 31-Jul-26 | 185,521 | $339.09 | $63m | 10-Q filed 29-Oct-26 |
| 30-Jun-26 | 129,966 | $328.13 | $43m | 10-Q filed 23-Jul-26 |